NASDAQ:YTEN   Yield10 Bioscience, Inc
Recent Accomplishments

Yield10 engaged a leading seed company to perform seed scale-up of three Camelina lines: E3902, a CRISPR edited high oil line; DH12, a doubled haploid elite line; and a disease resistant elite line. Seed scale-up of these lines is expected to enable future planting at the 100-to-1000 acre scale for subsequent larger scale planting and for producing oil and meal for customer sampling.

Yield10 began planting for its 2021 field trial program to evaluate several seed yield and oil content traits. In addition, the Company will conduct field trials and seed scale-up of two PHA containing Camelina lines. Planting is expected to be completed in the second quarter.

In the first quarter, the first U.S. patent (U.S. Patent No. 10,881,631) covering the co-production of the omega-3 fatty acids DHA and EPA in Camelina was granted to Rothamsted Research Ltd.

In April 2021, USDA-APHIS confirmed that new Camelina lines that had been CRISPR edited in the C3007 (BadC) gene are exempt from regulation under 7 CFR part 340. This clearance was obtained by Yield10 under the SECURE Rule, a new regulatory framework in the U.S. for regulating crops. In the first quarter, a U.S. patent (U.S. Patent No. 10,883,113) was granted to the University of Missouri covering modifications to C3007 genes to increase oil content in oilseed crops. Yield10 has an exclusive license to this technology.

Target 22$

If you need some amazing tools for full and part-time trading, check my profile to
follow me on twitter or check out my website and shop.